CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Newest patents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Close

Protein macroarrays for autoantibodies detection

Reference

04731-01

Patents status

French patent application FR1250956 filed on February 1st, 2012, entitled “Puces à protéines, préparation et utilisations”

Inventors

Franck CHATELAIN
Michel MAZZUCA
Véronique ROGEMOND
Marie Madeleine LARROQUE
Jérôme HONNORAT
Florian LESAGE

commercial status

Exclusive or non-exclusive licenses, Collaborative agreement

Laboratory

UMR7275 “Institut de Pharmacologie Moléculaire et Cellulaire (IPMC)” Valbonne, France, www.ipmc.cnrs.fr

Description

CONTEXT

Recently evidence for autoimmunity towards ion channels in central nervous system disorders has emerged. These disorders include Morvan’s syndrome, Rasmussen’s encephalitis, limbic encephalitis, multiple sclerosis, etc… Detection of such autoantibodies is useful for the  diagnosis and classification of these diseases.

TECHNICAL DESCRIPTION

This invention provides a unique method for detection of autoantibodies directed against membrane proteins. Anti-ion channel antibodies in the cerebrospinal fluid of patients are detected by using an ion channel macroarray. As a diagnostic tool, the method can be used to detect antibodies directed against specific targets. The method can also be used to identify new ion channel targets in patients that are not positive for antibodies directed against targets already known.

BENEFITS

This method has important advantages over current methods that are based on:
– Easier and cheaper
– 
Not restricted to targets already described

INDUSTRIAL APPLICATIONS

This innovation could be used for multiple applications as:
– Diagnosis and prognosis of autoimmune diseases
– 
Screening / Identification of new antigenic targets

DEVELOPMENT STAGE

Accomplished tests: Prototype available. The method has been validated using CSF from patients suffering of encephalitis with anti-NMDA receptor antibodies. 43 patients, 17 of them with anti-NMDAR antibodies detected by immunocytochemistry, were tested. 88% of the positive patients (15/17) were detected using the new method. The specifity for negative patients is 100%.

Current developments: detection of new targets in autoimmune disorders associated with hyperexcitability.

Prototype available

For further information, please contact us (Ref 04731-01)

 


Need further information ?

Contact us
Close

Contact us

  • This field is for validation purposes and should be left unchanged.
Close

Newest patents